Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 14/20 | 0.65 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.65 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.60 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.60 |
| ▸ | PTGFR | P43088 | 1/20 | 0.60 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.60 |
| ▸ | PDE2A | O00408 | 4/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.37 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10050631 | 0.91 | PTGER4 (0.68) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL2108724 | 0.89 | PTGER4 (0.71) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL10050533 | 0.89 | PTGER4 (0.76) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL10019023 | 0.86 | PTGER4 (0.85) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL2109496 | 0.86 | PTGER4 (0.84) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL10019038 | 0.85 | PTGER4 (0.65) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| Potassium Ion SCHEMBL2109494 | 0.85 | PTGER4 (0.72) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL10050711 | 0.83 | PTGER4 (0.80) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL25376489 | 0.81 | PTGER4 (0.79) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL31610949 | 0.81 | PTGER4 (0.69) | PTGER4PTGDRPTGER2TBXA2RPTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114877-B1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK CANADA INC (CA) | 2012-12-26 | — | — | EP | disclosed |
| US-8158671-B2 | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists | MERCK CANADA INC. (CA) | 2012-04-17 | — | — | US | disclosed |
| US-20090318518-A1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK CANADA INC. (CA) | 2009-12-24 | — | — | US | disclosed |
| WO-2008104055-A1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318518-A1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGDR 10/4885PTGER2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.